Washington Lawmaker Tables Bill Allowing CBD in Food

January 14, 2020 09:00:04

The cannabidiol (CBD) industry is a lot stranger than most sectors. For starters, most industries take a while to pick up steam and get rolling, but barely a year after CBD became legal, the market for the hemp extract is worth at least a billion dollars, and experts believe it will hit $20 billion by 2024. This is despite the fact that the industry is barely regulated, with the exception of the 2018 Farm Bill which legalized industrial hemp.

The legislation classified cannabis with less than 0.3% THC levels as hemp, and for CBD to be legal, it also has to have similar levels of THC (delta-9 tetrahydrocannabinol). It is the chemical in cannabis that produces the plant’s infamous ‘high’.

Although the FDA has admitted that it doesn’t have enough information to term cannabidiol as generally recognized as safe (GRAS), and taken steps to prevent companies from selling CBD-infused food and drinks, people have still been flocking to buy these products.

A Washington lawmaker recently tabled a bill that would allow companies to sell CBD in food, although it is in stark opposition to federal and state regulations concerning cannabidiol in food. Tabled on January 7 by Republican Rep. Drew MacEwen, the bill will allow processors to put CBD in food and beverages.

The legislation has received a lukewarm response. Agriculture Department spokesman Chris McGann says that there are still concerns about allowing CBD in food. “A state-led effort to allow food ingredients not allowed by the FDA would be complicated to enforce and put processors and markets at risk.”

Last year, the FDA sent letters to several companies, warning them of selling CBD-infused foods and claiming their therapeutic benefits. Tons of users claim cannabidiol is medically effective against a variety of illnesses, ranging from anxiety and high blood pressure to insomnia. However, there’s little scientific research to back these claims, and most industry players agree that more research is needed.

The only FDA approved CBD drug is Epidiolex, and it’s used to manage seizures in two rare and hard to treat pediatric epilepsies.

Industrial Hemp Association of Washington director Bonny Bo Peterson says the new state bill to allow CBD in foods is ‘useless’, arguing that it won’t stop the FDA from coming in and saying, “Hey, you can’t do this.”

Drew MacEwen, the Bill’s sponsor, and the FDA haven’t made any public comments regarding the pending legislation.

It is likely that the CBD industry, including companies like Sugarmade Inc. (OTCQB: SGMD) and Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF), may be watching how this bill is handled by the Washington legislature. After all, states have defied federal law before by legalizing marijuana so there is a slim possibility that the same could happen for CBD.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.